ijms-logo

Journal Browser

Journal Browser

Toxic Liver Injury: Molecular, Mechanistic, and Medical Challenges 3.0

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Endocrinology and Metabolism".

Deadline for manuscript submissions: closed (15 April 2024) | Viewed by 360

Special Issue Editor


E-Mail
Guest Editor
Department of Internal Medicine II, Division of Gastroenterology and Hepatology, Klinikum Hanau, Teaching Hospital of the Goethe University, 999035 Frankfurt, Germany
Interests: Heavy metals; Heavy metal uptake; Heavy metal disposition, Heavy metal homeostasis; Haber Weiss reaction; Fenton reaction; Benefits and risks for human health; Environmental pollution
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues, 

Liver injury by potentially toxic exogenous and endogenous compounds represents major molecular, mechanistic, and medical challenges. Among the hepatotoxic exogenous compounds are conventional drugs, herbal drugs including various traditional herbal products and so-called herbal supplements lacking supplementary features in patients with a normal balanced diet, alcoholic beverages, industrial chemicals such as aliphatic halogenated hydrocarbons like carbon tetrachloride, environmental chemicals such as heavy metals, nature-based products, and compounds ingested with some fungi. Endogenous hepatotoxic compounds are found in individuals suffering from hereditary diseases such as hemochromatosis caused by iron overload, Wilson disease due to copper overload, Gaucher disease caused by accumulation of glucocerebroside, hepatic porphyria due to metabolic problems of hem synthesis, and a vast range of other hereditary diseases. Finally, much interest has focused more recently on molecular, mechanistic, and clinical aspects on overweight patients with nonalcoholic fatty liver disease and progression to nonalcoholic steatonecrosis (NASH) and nonalcoholic liver cirrhosis, including rare hepatocellular carcinoma. Submissions to the International Journal of Molecular Sciences with a current IF of 4.5 are welcome with focus on molecular, mechanistic, and medical challenges; discouraged are purely clinical papers. 

Prof. Dr. Rolf Teschke
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • liver injury

  • nonalcoholic fatty liver disease
  • nonalcoholic steatonecrosis
  • nonalcoholic liver cirrhosis
  • hepatocellular carcinoma

Published Papers

There is no accepted submissions to this special issue at this moment.
Back to TopTop